🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Join us to review exciting ASCO #GI25 meeting research. John Marshall, Benjamin Weinberg, MD, FACP, Ruth He, MD, PhD, Reetu Mukherji, MD will highlight the most compelling abstracts in Colorectal, Pancreatic, Liver, and Upper GI cancers. Register today for Zoom link: bit.ly/3yFhuvr

Don’t miss Dr. Jennifer A. Marks, MD at the Texas Lung Cancer Conference in Austin, TX! This 2-day CE accredited conference brings together top oncology experts to discuss impactful updates and strategies for treating lung cancer. Learn more: hubs.la/Q0344cdY0 #TexasLung25 #LCSM

Join Us for the 2025 Johns Hopkins Updates in GI Cancers! Don’t miss this power-packed two-day conference on February 7-8, featuring the latest in GI Oncology. I’ll be speaking on PRRT and its role in NET management, alongside an incredible lineup of experts. 📌 Register now:

Join us tomorrow, Feb 7th, to review ASCO #GI25 meeting research with the Cure GI Cancers. John Marshall, Benjamin Weinberg, MD, FACP, Ruth He, MD, PhD, Marcus S. Noel, and Reetu Mukherji, MD will highlight the most compelling abstracts in Colorectal, Pancreatic, Liver, and Upper GI cancers. Register today

Combining Local Therapy and Immunotherapy in Intermediate Stage HCC - Beau Bosko Toskich, MD FSIR Ruth He, MD, PhD HCC CONNECT Digestive Cancers Europe Global Liver Institute European Liver Patients' Association oncodaily.com/blog/beau-bosk… #Immunotherapy #IO #ImmuneOnc #HCC #LiverCancer #Cancer #OncoDaily #Medicine #Oncology #MedEd #MedX

Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for HCC The Lancet doi.org/10.1016/S0140-… 🔎CheckMate 9DW 👉mOS 23·7 vs 20·6 mo 👉ORR 36 vs 13% 👉Consistent efficacy in ALBI 1 and 2 🧐Great new option for 1st line HCC ESMO - Eur. Oncology EASL Education ILCA

Pts with intermediate stage #HCC may benefit from multimodal strategies, combining IO with locoregional therapies ️ ➡️ Are you updated on the latest data combining IO with locoregional therapies? ➡️ What’s the role of the multidisciplinary team? Get all the answers in this

It has been 2 m since I joined Columbia. With support of colleagues in Hem/Onc and center for liver disease and transplant, I feel well settled into my new role. For those interested, here is my link: cancer.columbia.edu/profile/aiwu-r…, for new patient: [email protected]

Working closely with my multidisciplinary team, I am excited to serve patients in and around the Big Apple, and begin new research projects in liver and biliary cancers. Please check out our website, which is currently being built and updated regularly: columbiasurgery.org/liver/liver-ca…

Why #Y90? At ILCA #STW25, we explored evolving strategies in #HCC & #BTCs with top experts in liver cancer. Missed the live discussion on 6 June in Chicago? 🎥Session recordings are now available at ILCA website: ilcalive.org/single-topic-w…

Incredible news! #LR5 (Definite #HCC) criteria of #LIRADS, including #CEUS, are now fully aligned with #OPTN #liver #transplant United Network for Organ Sharing (UNOS) American College of Radiology kathrynfowler optn.transplant.hrsa.gov/media/ojdh4qi1…

Honored and humbled to accept a new role as Division Chief for Hematology & Oncology at Georgetown starting next month. Excited for all that the future holds for Georgetown University Georgetown Lombardi with the best colleagues one could ask for.

Stephen, congratulations!

Cool! 😀

Mike, congratulations!

Fresh off the press! Benjamin Weinberg, MD, FACP Reetu Mukherji, MD Marcus S. Noel John Marshall Ruth He, MD, PhD , Thanks for your contribution to this project. Special thanks to Dr.Narayanan Sadagopan, our graduating fellow. nam02.safelinks.protection.outlook.com/?url=https%3A%….

From palliative care a decade ago to first-line curative intent treatment today, #Y90 radiation segmentectomy has been a welcome advancement in #livercancer treatment. 🧩 pubs.rsna.org/doi/epdf/10.11… RSNA Society of Interventional Radiology CIRSE APASL News 日本肝臓学会 ESMO - Eur. Oncology BCLC GROUP

.Benjamin Weinberg, MD, FACP, discussed early results from the phase 2 EXPEL PANC trial (NCT05558982), evaluating BXCL701 plus pembrolizumab (Keytruda) in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) after progression on chemotherapy. onclive.com/view/five-unde… via @onclive